Patients whose breast cancer converted from lymph node-positive to lymph node-negative after neoadjuvant chemotherapy did not have a higher risk of recurrence or death when they skipped adjuvant regional nodal irradiation (RNI), according to a clinical trial. The study’s findings suggest that downstaging cancer-positive regional lymph nodes with neoadjuvant chemotherapy can let some patients skip adjuvant RNI without harming oncologic outcomes.
StockWatch: Sarepta CEO Defends Elevidys as Q4 Sales Fall Short
SAN FRANCISCO—No sooner did the J.P. Morgan 44th Annual Healthcare Conference kick off when Sarepta Therapeutics (SRPT) saw its stock skid 11% after the company
